Découvrez le replay de notre dernière rencontre actionnaires à Paris 👨💻 Mercredi 11 décembre, nous avons eu le plaisir de recevoir plusieurs actionnaires d’Innate Pharma pour une présentation des dernières actualités de la Société et échanger sur la stratégie et l’évolution du portefeuille. Visionnez notre présentation et la séquence de questions-réponses ici : https://lnkd.in/e8f4cS9K Merci à toutes les personnes présentes pour ce moment privilégié. #InnatePharma #Actionnaires #EvenementActionnaires #Bourse
About us
Innate Pharma S.A. is a global, clinical-stage oncology-focused biotech company dedicated to improving treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer. Innate Pharma’s broad pipeline of antibodies includes several potentially first-in-class clinical and preclinical candidates in cancers with high unmet medical need. Innate has been a pioneer in the understanding of natural killer cell (NK cell) biology and has expanded its expertise in the tumor microenvironment and tumor-antigens, as well as antibody engineering. This innovative approach has resulted in a diversified proprietary portfolio and major alliances with leaders in the biopharmaceutical industry including Bristol-Myers Squibb Novo Nordisk A/S, Sanofi, and a multi-products collaboration with AstraZeneca. Based in Marseille, France, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.
- Website
-
https://www.innate-pharma.com/
External link for Innate Pharma
- Industry
- Biotechnology Research
- Company size
- 201-500 employees
- Headquarters
- Marseille, Provence-Alpes-Côte d’Azur
- Type
- Public Company
- Founded
- 1999
- Specialties
- biotechnologies, antibodies, immunotherapy, and oncology
Locations
-
Primary
Get directions
117, Avenue de Luminy
Marseille, Provence-Alpes-Côte d’Azur 13009, FR
-
Get directions
2273 Research Blvd
Suite 350
Rockville, Maryland 20850, US
Employees at Innate Pharma
Updates
-
En direct du Paris Trocadéro - Business Center 🚀 Merci à tous nos actionnaires présents pour ce moment d’échanges ! C'est un véritable plaisir pour le management d'Innate Pharma de partager les avancées de notre portefeuille et les perspectives de la société. Merci au Dr. Martine Bagot pour sa participation et la présentation des données de lacutamab dans les lymphomes T cutanés. #InnatePharma #Actionnaires #EvenementActionnaires #Bourse
-
-
#MeetInnate Nous avons le plaisir de vous rappeler que la rencontre actionnaires aura lieu ce mercredi à Paris. La présentation du portefeuille d’Innate Pharma par notre équipe de direction sera suivie d’un moment d’échanges sur les dernières actualités de notre société. 📅 Date : Mercredi 11 décembre 📍 Lieu : Paris 🕓 Heure : 17h30 – 19h00 #InnatePharma #Actionnaires #EvenementActionnaires #Bourse
-
-
Chers actionnaires, notre nouvelle lettre est en ligne ! 📢 Dans cette édition, retrouvez : 📽️ L’interview de Jonathan Dickinson suite à sa nomination en tant que Président du Directoire d’Innate Pharma 🚀 Les éléments clés du 3ème trimestre 2024 📊 Un retour sur la présentation à l’ASH 2024 de nouvelles données prometteuses de l’étude de Phase 2 TELLOMAK évaluant lacutamab 🤝 Les informations sur notre prochaine réunion actionnaires 🗓️ Notre calendrier financier 2025 Pour rejoindre notre Club des Actionnaires, inscrivez-vous ici : https://lnkd.in/eKsSHbiy #InnatePharma #Actionnaire #Newsletter
-
-
Thanks to Brad Loncar for meeting and talking to our new CEO Jonathan Dickinson during American Society of Hematology 2024. See you soon in Marseille!
𝐀𝐒𝐇 𝟐𝟎𝟐𝟒: The new CEO of Innate Pharma on taking the job and the company's work on antibodies, engagers, and ADCs. #ASH24 Jonathan Dickinson describes what appealed to him about Innate. He discusses the pipeline, including ASH data from the lead program Lacutamab and an NK engager program Sanofi is partnered on. Full video: https://lnkd.in/gAZsgvJJ BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Allucent | NYSE | Klein Hersh
-
Innate Pharma presented at American Society of Hematology 2024 new data highlighting the quality-of-life improvements observed in patients with cutaneous T-cell lymphoma (CTCL) treated with lacutamab in the TELLOMAK Phase 2 clinical study. Patients with relapsed or refractory CTCL face limited treatment options and often report lower health-related quality of life, particularly those in advanced stages. TELLOMAK's findings reveal promising signs that lacutamab may help alleviate some of the most distressing symptoms of this disease early on treatment. Learn more in the press release: https://lnkd.in/eV9FaGqp #InnatePharma #ASH2024
-
Thank you to Citi for hosting us at the Citi 2024 Global Healthcare Conference. We appreciated the opportunity to connect and exchange insights with such an engaged audience! For those who couldn’t join us live, the replay is now available. Don’t miss the chance to catch up on the key takeaways and updates: 📌 https://lnkd.in/gdAH5rsz #CitiHealthcareConference
-
-
Innate Pharma and the IFLI - Institute for Follicular Lymphoma Innovation are pleased to announce a new agreement to clinically study the potential of IPH6501, Innate's anti-CD20 ANKET® in Follicular Lymphoma. Patients with R/R Follicular Lymphoma will be included in the ongoing Phase 1/2 trial investigating IPH6501 in patients with R/R CD20+ Non-Hodgkin Lymphoma To support Innate and the investigation of IPH6501 in Follicular Lymphoma, the IFLI will invest up to $7.9M. Learn more: https://lnkd.in/gmygWPZU #InnatePharma #ANKET #agreement #FollicularLymphoma
-
#MeetInnate Today, meet Jonathan Dickinson, CEO and the executive team of Innate Pharma at the Citi's Global Healthcare Conference, Miami, USA 🔗 Join the fireside chat at 1:00 PM ET this December 5, 2024. Register via this link: https://lnkd.in/gdAH5rsz We look forward to meeting you. #InnatePharma #InvestorConference #Citi
-
-
Thank you Evercore for hosting us today at the 7th Annual Evercore ISI HealthCONx Conference! It was a pleasure to engage in such great discussion. The webcast of the fireside chat is now available at this link: https://lnkd.in/eEZb7MMs #InnatePharma #Evercore #HealthCONx2024
-